Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CYTARABINE Cause Malignant neoplasm progression? 728 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 728 reports of Malignant neoplasm progression have been filed in association with CYTARABINE (cytarabine). This represents 1.6% of all adverse event reports for CYTARABINE.

728
Reports of Malignant neoplasm progression with CYTARABINE
1.6%
of all CYTARABINE reports
247
Deaths
174
Hospitalizations

How Dangerous Is Malignant neoplasm progression From CYTARABINE?

Of the 728 reports, 247 (33.9%) resulted in death, 174 (23.9%) required hospitalization, and 52 (7.1%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CYTARABINE. However, 728 reports have been filed with the FAERS database.

What Other Side Effects Does CYTARABINE Cause?

Febrile neutropenia (6,142) Off label use (4,183) Pyrexia (2,992) Neutropenia (2,558) Disease progression (2,352) Drug ineffective (2,281) Thrombocytopenia (2,148) Sepsis (2,013) Myelosuppression (1,869) Product use in unapproved indication (1,619)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which CYTARABINE Alternatives Have Lower Malignant neoplasm progression Risk?

CYTARABINE vs CYTARABINE\DAUNORUBICIN CYTARABINE vs DABIGATRAN CYTARABINE vs DABIGATRAN ETEXILATE CYTARABINE vs DABRAFENIB CYTARABINE vs DABRAFENIB\TRAMETINIB

Related Pages

CYTARABINE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression CYTARABINE Demographics